Vilin Bio Med Ltd (VILINBIO) is currently trading at 50.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vilin Bio Med Limited is a Hyderabad-registered, Roorkee-based pharmaceutical manufacturer focused on oral liquids, tablets, capsules, dry syrups and topical formulations across Beta-Lactam and Non-Beta-Lactam therapeutic categories, operating a single manufacturing facility and an R&D foundation to support product approvals and formulation development. Financially, H1 FY26 revenue jumped to Rs. 966.40 lakhs from Rs. 449.32 lakhs a year earlier, reflecting a strong sequential and year-on-year recovery in sales volumes and realizations, while full year audited revenue figures show the company operating at a modest scale relative to larger Indian generics players. Profitability remains thin: H1 FY26 net profit was only Rs. 15.17 lakhs and PBT was Rs. 19.38 lakhs, implying margins near or below two percent; this highlights operational leverage and cost sensitivity for Vilin Bio Med Limited given commodity input and financing costs. Balance sheet dynamics show rising inventories to Rs. 612.38 lakhs, trade receivables of Rs. 554.63 lakhs and long-term borrowings of Rs. 2,321.52 lakhs; however operating cash flow turned positive in H1 FY26 to Rs. 38.87 lakhs, suggesting working capital normalization after prior year stress. Operationally, the company retains a diversified dosage-form mix and claims over 1,000 drug approvals historically, which combined with Roorkee manufacturing and a small sachet and non-beta facility gives Vilin Bio Med Limited product breadth and R&D support to pursue domestic generics demand.

Over the past 52 weeks, Vilin Bio Med Ltd has traded between a low of ₹18.95 and a high of ₹60.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vilin Bio Med Ltd has a market capitalization of approximately 77.70. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vilin Bio Med Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 40.26 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 77.70 Cr, Vilin Bio Med Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vilin Bio Med Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vilin Bio Med Ltd is 40.26. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The data shows ₹59.00 as on 16-Sep-2026 10:33:07 IST. It also mentions ₹58.95 as on 10-Sep-2026.

Vilin Bio Med trades on NSE under the symbol VILINBIO.